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ABSTRACT
The ability of pharmaceutical excipients to exhibit significant bioactivity independent of the active
pharmaceutical ingredient is beginning to be recognized. Certain types of diets or foods have been
demonstrated to alleviate diabetic symptoms. Because most excipients are derivatives of food
products, it is not unreasonable to assume that these molecules are responsible at least in part for the
diabetes ameliorative properties of such foods or food products. Indeed, evidence has accumulated
that such excipients act on well defined pharmacologic pathways and targets in order to exercise
their beneficial effects. If excipients that act on multiple diabetogenic pharmacologic targets or
pathways are combined together in concentrations that are at or above their recommended dietary
allowances, the possibility exists that such a formulation may provide “stand alone” control of type
II diabetes. The formulation could be as simple as a mixture of these solid powders presented in a
‘sachet’ or pack to be mixed with water and taken once or twice a day.
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INTRODUCTION
There has been increasing evidence in recent
years that pharmaceutical excipients may not be
innocuous, “inert” components of a dosage
form, but may possess either “stand alone”
biological activity or may act to change the
biological activity of the active pharmaceutical
ingredient (API). Excipients may inhibit drug
metabolizing, cytochrome P-450 enzymes,
modify drug pharmacokinetics, alter the efflux
of drug from cells or enhance gene transfection
efficiency and nuclear localization. 
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Because most excipients have historically origi- 
nated from food or food products, they have
been assigned - and in most cases;
experimentally proven to have - generalized
pharmacological bioactivity profiles based on
the ingestion of those particular food products.
For example, oils, green leafy vegetables and
nuts have antioxidant and cardioprotective
p r o p e r t i e s .  F i s h  o i l  ( c o n t a i n i n g
docosahexaenoic acid [DHA]) has anti-
inflammatory properties. Whole grains, fruits
and vegetables contain fiber (e.g. guar gum)
that decreases the incidences of non-infective
diseases of the bowel and promotes
cardiovascular health. Coconut oil contains
medium  chain  triglycerides  (MCTs’)  and  has 
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Table 1 GNC Preventative Nutrition Diabetic Nutrition Plan Dietary Supplement Packs (as presented in
www.GNC.com)
Glucose Support Formula™





 Vitamin E (as d-alpha tocopherol)  30 IU   100%
 Vitamin B-6 (as pyridoxine hydrochloride)  1 mg  50%
 Folic Acid  200 mcg  50%
 Vitamin B-12 (as cyanocobalamin)  3 mg  50%
 Biotin  125 mg  42%
 Selenium (as sodium selenate)  70 mcg  100%
 Manganese (as manganese gluconate)  2.5 mg   125%
 Chromium (as chromium picolinate)  200 mcg   167%
 alpha-Lipoic Acid  600 mg  *
Fenugreek Seed Powder (Trigonella foenum-
graecum)
  500 mg  *
* Daily Value not established
Other Ingredients: Soybean Oil, Gelatin, Glycerin, Soy Lecithin, Caramel Color, Titanium Dioxide
(natural mineral whitener)
been historically used as a “functional food” to
cure a multitude of ailments (1). The advent of
detailed knowledge of mechanisms of action of
these ingredients has prompted their distillation
into individual “nutritional supplements” in
order to alleviate specific deficiencies of
individual diets. Tables 1 and 2 list the
ingredients of two commonly used dietary
supplements designed to have antidiabetic
properties.
HYPOTHESIS AND DEVELOPMENT OF
THE CONCEPT
The purpose of the manuscript is to propose a
formulation consisting entirely of excipients or
food chemicals that may demonstrate clinical
efficacy in controlling the symptoms of type II
diabetes. It requires but one more step to
realize that a combination of such excipients,
food chemicals or food additives may provide
protection against diabetes or insulin resistance;
that may be comparable to the effects of single
API’s;  due to their effects on multiple
pathways and targets. Some potential molecules
that may prove worthy of consideration for
such a formulation are discussed below:
Table 2: Glucocil  antidiabetic supplement™
ingredients (as presented at www.glucocil.com)
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L-Arginine
It was demonstrated that L-Arginine
significantly improved peripheral and hepatic
insulin sensitivity in type 2 diabetic patients (2).
L-Arginine, a precursor for the synthesis of
nitric oxide (NO), caused an increase in the
depressed cGMP (the second messenger of
NO) levels of diabetic subjects thereby
attenuating insulin resistance partly by
normalizing the vasodilatory response (3) and
partly by increasing glucose transport (4).
L-Arginine is an excipient in the tissue
plasminogen activator formulation, Activase .®
Niacin (Nicotinic acid)
Incomplete suppression of lipolysis by insulin
in the fed state in insulin-resistant subjects leads
to increased lipolysis in adipose tissue with
elevated circulating free fatty acids (FFA) and
in the eventual development of the atherogenic
dys-lipidaemic phenotype. It has been
demonstrated that FFA cause hepatic and
skeletal muscle insulin resistance by inhibiting
insulin suppression of glycogenolysis (5) and by
increasing the flux of fructose-6-phosphate into
the hexosamine pathway (6) respectively. FFA
also induce insulin resistance in muscle cells by
interfering with phosphatidylinositol 3-kinase
(PI3K) activity which in turn causes reduced
translocation of GLUT4 (the transport protein
that facilitates glucose diffusion into cells) to
the cell surface (7). Niacin suppresses lipolysis
in adipose tissue, thereby leading to a decreased
flux of FFA to the liver with reduced very low
density lipoprotein (VLDL) production. The
anti-atherogenic effects of niacin on the lipid
profile hence may mitigate hepatic insulin
resistance as well as attenuate a major source of
cardiovascular risk in insulin-resistant
populations (8). Niacin is present as an
excipient to discourage addictive narcotic
opioid dosing in Acurox™ tablets (9).
Magnesium
2Oral supplementation with MgCl  solution has
been shown to restore serum magnesium levels,
improve insulin sensitivity and metabolic
control in type 2 patients that exhibit decreased
serum magnesium levels (10). The mechanism
of action has been suggested to be a restoration
of the defective tryrosine kinase activity of
insulin receptors that is observed in
hypomagnesemia (11). Magnesium stearate is
used as a glidant in the manufacture of tablets,
magnesium carbonate is used as an excipient in
Tenormin .™
Guar gum
Guar gum and other fiber analogs increase the
gastric emptying time, reduce the rate of
glucose formation (by inhibition of
dissaccharidases) (12) and reduce the rate of
glucose absorption from the small intestine
(13). The increased viscosity seems to be the
cornerstone of their efficacy. Highly viscous or
gel forming fibers also increase satiety, thereby
mimicking calorie restriction, which has the
effect of upregulation of Sirtuin 1 (SIRT1).
SIRT1 upregulation stimulates glucose-
dependent insulin secretion from pancreatic â
cells and attenuates insulin resistance through
its modulation of adiponectin secretion,
gluconeogenesis, inflammatory responses and
levels of reactive oxygen species (14).
Plasminogen activator inhibitor-1 activity,
which correlates strongly with the degree of
insulin resistance, is also lowered by guar gum.
Guar gum is used as a binder in the
manufacture of tablets, as a viscosity modifier
in suspensions or syrups.
D-chiro-Inositol
D-chiro-inositol may act to bypass a defective
normal in-vivo epimerization of myo-inositol to
D-chiro-inositol associated with insulin
resistance and act to partially restore insulin
sensitivity and glucose disposal (15). Myo-
inositol is an excipient used in dry powder
inhalable vaccines in the preclinical stage (16).
Because D-Chiro-inositol is a stereoisomer of
myo-inositol, it is expected that the latter can
be used without any significant safety issues in
humans as well.
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Vitamin E
It has been demonstrated that reactive oxygen
species play a causal role in multiple forms of
insulin resistance (17). Albeit transient, vitamin
E has been shown to improve insulin resistance
in human subjects (18). FFA induced activation
of Nuclear factor-kappaB (NF-kB) has been
shown to be associated with the development
of insulin resistance via the serine
phosphorylation of Insulin receptor substrate-1
(IRS-1) and subsequent downstream
interference with Phosphoinositide 3 kinase
(PI3K) association (19). The FFA induced
NFkB activation can be prevented by Vitamin
E (20). Vitamin E is sometimes added as an
antioxidant to vegetable oils.
Docosahexaenoic acid (DHA)
Omega-3 fatty acids elicit hypotriglyceridemic
effects by coordinately suppressing hepatic
lipogenesis, upregulating fatty oxidation in the
liver and skeletal muscle through peroxisome
proliferator activated receptor (PPAR)
activation, and enhancing flux of glucose to
glycogen through downregulation of hepatocyte
nuclear factor (HNF-4á). The net result is the
repartitioning of metabolic fuel from
triglyceride storage toward oxidation, thereby
reducing the substrate available for VLDL
synthesis (21). DHA is used as a food additive
in dairy items such as milk and yogurt.
Acetic acid
The addition of vinegar to high glycemic load
meals has been shown to result in significantly
reduced postprandial glycemia. This effect has
been attributed in part to a suppression of
intestinal disaccharidase activity by acetic acid
(22, 23) and is independent of gastric emptying
time (24). Acetic acid is a constituent  of
vinegar.
Lecithin
Impairment of Stat-3 activation and reduction
of PPARá activity contributes in part to leptin
resistance and consequently, obesity (25).
Obesity, in turn, contributes to the modulation
of multiple signaling pathways and effectors
such as Leptin, NF-kB, FFA, SIRT1, that – in
concert – contribute to insulin resistance.
PPAR agonists partly restore the liver’s capacity
to oxidize fatty acids and attenuate insulin
resistance. It has been demonstrated that 1-
palmitoyl-2-oleoyl-sn-glycerol-3-phospho-
choline, a component of lecithin, is an endo-
genous ligand for PPARá in the liver (26). This
substance is a component of lecithin, which has
long been used in food additives and in
intravenous fat emulsions primarily for its
emulsification properties.
Alpha-Lipoic acid
Copious anecdotal evidence exists regarding
the efficacy of alpha-lipoic acid in restoring
insulin sensitivity in type 2 diabetes. Alpha
lipoic acid has been demonstrated to inhibit
mammalian pyruvate dehydrogenase kinase,
thereby  providing a possible mechanism for a
glucose (and lactate) lowering effect  in diabetic
subjects (27).
Caprylic/capric triglyceride
Adenosine receptor agonists have been
demonstrated to prevent diabetes development
in murine models, in part due to the
suppression of pro-inflammatory cytokine
expression (28). Miglyol , a medium chain®
triglyceride (MCT) of caprylic and capric acids,
has been shown to upregulate adenosine
receptors, A3 and A2A (29). MCT
administration has been shown to increase
insulin mediated glucose disposal (30) and to
decrease insulin resistance (31). Miglyol is a
solubilizer  that is widely used in various
approved drug products.
DISCUSSION
Almost every molecule has at least some
measurable affinity toward a target receptor.
Such affinity may neither necessarily be very
specific nor very high, so that therapeutic
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modulation of the target receptor and/or
signaling pathway may not be enabled. Many of
the “bioactive excipients” listed in table 3 have
been reported to possess non-specific affinities
toward a myriad of target receptors because:
1. Many of them act by mechanisms of action
that are generic to the activation of multiple
targets, one of them being redox and/or
free radical manipulation. 
2. Many of them function as cofactors of
enzymes.
3. Many are (or activate) precursors of second
messengers that propagate signal
transduction.
Such non-specificity exhibited by these
individual “bioactive excipients” may tend to
attenuate their (individual) actions on the
desired target specific biochemical signaling
pathway, necessitating either the administration
of much larger doses of individual excipients in
order to achieve therapeutic effects, or
administering most or all of these “bioactive
excipients” concurrently.  The latter concept is
based on the proposition that an ideal drug may
be one whose efficacy is based not on the
modulation of a single target, but rather on the
rebalancing of the several proteins, or events,
that contribute to the etiology, pathogeneses ,
and progression of diseases, i.e., in effect a
promiscuous drug (32). For example, in some
instances, herbal extracts with anti-diabetic
properties have been demonstrated to be “bio-
equivalent” to FDA approved drugs based on
efficacy in animal models. 
When combined with bioenhancers/
solubilizers, the hypoglycemic activity of an
extract of  Artemisia  dracunculus L  containing at
least 6 bioactive compounds was shown to be
comparable to the activity of the anti-diabetic
drug metformin (33). This lends credence to
the observation that the multicomponent and
multimechanistic advantage of botanical
preparations compared to single chemical
entities derives in part due to their promiscuity
in targeting multiple pharmacologic targets (34,
35) and there seems to be no reason; a’ priori;
why these advantages should not also translate
to a mixture of ‘bioactive’ pharmaceutical
excipients. Co-administering these excipients/
excipient constituents /food additives provides
this advantage that is especially relevant for a
disease such as non-insulin dependent diabetes
whose etiology is multifactorial in nature and
whose predisposing factors – such as obesity –
are associated with a state of generalized
chronic low level inflammation (36).
Table 3 compares the recommended dietary
allowances of the excipients demonstrating
pharmacological bioactivity toward attenuating
type II diabetic symptoms versus their use in
clinical studies obtained from the literature. A
proposed amount of each ingredient to be
included in the formulation is also presented
per the criteria described below.
Column 3 in table 3 indicates the amounts of
these bioactive excipients (per day) that have
been used as supplements in human clinical
studies. Vitamin E supplementation reduced
glucose AUC, increased glucose disappearance,
increased total glucose disposal and increased
non oxidative glucose metabolism (37). Niacin-
treated subjects experienced significantly
reduced total cholesterol and triglyceride levels
2(38). Oral supplementation with MgCl  solution
restored serum magnesium levels, improving
insulin sensitivity and metabolic control in type
2 diabetic patients with decreased serum
magnesium levels (39).  Guar gum
supplementation participants that had the
highest mean fasting blood glucose and HbA1c
levels, showed a significant reduction in their
fasting glycemic levels as well as a significant
reduction in total cholesterol levels (40).
Arginine, in an amount likely to be ingested in
a high-protein meal, did not stimulate insulin
secretion but attenuated the increase in glucose
when given with glucose (41).
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Table 3  Excipients or food chemicals used in human clinical studies that demonstrate a beneficial effect in
biomarkers of type-2 diabetes.
Ingredient RDA  (per1
day)
Supplementation amounts 





Vitamin E 15 mg 900 mg 900 mg
Niacin 20 mg 500 mg 500 mg
Magnesium 400 mg 1 g 400 mg
Inositol ~ 30 mg 100 mg 30 mg
Guar gum 25 g 10 g 10 g2
L-Arginine 3.5 – 5.0 g 10.6 g 3.5 g
Docosahexaenoic acid 500 mg 1.5 g 500 mg
Lecithin Not established 3.6 g 3.6 g
Caprylic/Capric acid Not established 5 g 5 g
Alpha lipoic acid Not established 600 mg 600 mg
Sodium acetate/Acetic acid
(acetate buffer)
Not applicable Not applicable Buffering agent
1. Recommended dietary allowance.
2. As dietary fiber.
3. Calculated as described below. Total weight is 25.3 g packaged in two, 15 g sachets, to be taken twice a day each with a glassful of water.
Supplementation of DHA in men and women
with below-average HDL cholesterol
concentrations raised the LDL cholesterol level,
but had favorable effects on triglycerides, the
triglyceride/HDL cholesterol ratio and the
fraction of LDL cholesterol carried by small,
dense particles (42). Orally administered alpha
lipoic acid increased insulin stimulated glucose
disposal in significantly more subjects when
compared to placebo (43). MCT administration
as part of daily food intake showed a reduction
in body weight, cholesterol and a reduction in
homeostasis model assessment of insulin
resistance (31).
PROPOSED FORMULATION
Because most of the ingredients in Table 3 are
found in foods; either as minor constituents or
as additives, it should theoretically be possible
to make dietary adjustments so that these
ingredients are ingested in sufficient amounts.
However, in practice, dietary habits are not
easily modified and ingestion of significantly
large amounts of food substances would be 
required at least for those ingredients that are
present as food additives.
Because of the (postulated) synergistic effects
of the combined ingredients due to the
principle of promiscuity (see above), it should
be possible to decrease the supplementation
amount for each ingredient without sacrificing
biological efficacy for the mixed ingredients. As
a crude first approximation, if the amount used
for a particular ingredient in clinical studies is
more than an order of magnitude greater than
the RDA, then the proposed formulation will
utilize the former. If the amount used for a
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particular ingredient in clinical studies is less
than the RDA, then the RDA amount will be
utilized in the formulation. Where the RDA is
not specified, the amount used in clinical trials
will be used in the proposed formulation
(Column 4 of Table 3). The total weight of
ingredients in the proposed formulation is
calculated to be 25.3 g. 
The dosage form could hence be presented as
two ~ 15 g “sachets” or packs containing the
solid ingredients. Each sachet would be taken
(for example) with a glass of water. Two
sachets per day would constitute a long term
management therapy for diabetes. The
formulation would presumably also need to
include; at a minimum; glidant(s) and flavors to
improve the manufacturability and palatability
of the dosage form. 
LIMITATIONS
1. Although each ingredient alone has been
demonstrated to act via well studied and
validated signaling pathways, the
modulation of which results in the
amelioration of the symptoms and/or the
aetiology of diabetes; there can be no
assurance that the combination of all these
ingredients will act additively or
synergistically. They may, in fact, act
entirely out of concert with each other that
negate their individual or combined
beneficial effects.
2. Most of the signaling pathways or
mechanisms of action have not been
studied in humans. Furthermore, quite a
few have been studied in vitro. The results
of these experiments cannot be
extrapolated to their actions in vivo in
humans. Well controlled clinical studies
using such a combination of excipients are
necessary in humans before any
justification for efficacy can be claimed.
3. The paradigm of administering “bioactive
excipients” is possible for diseases that are
chronic in nature and for whom gradual
and lasting beneficial effects may be
observed from the modulation of signaling
pathways that lead to incremental but
discernible improvements in the quality of
life. Such “bioactive excipients” may not be
effective for acute diseases for which
drastic interventions are required such as
pathogenic infections, cancer, or organ or
t issue (neuromuscular,  cognit ive)
deterioration which can irreversibly affect
the capacity to function normally.
4. The calculation for the amount of each
ingredient to be used in the proposed
formulation assumes a “one size fits all”
paradigm and discounts the differing
predominance of one (or more) etiological
factors for different patients. For example,
the relative contributions of dyslipidemia,
hypomagnesimia, oxidative stress,
inflammation, obesity and mitochondrial
function (etc.) toward disease progression
may be different for different individuals.
Individual patients would be better treated
with a dosage form containing relative
concentrations of individual ingredients
that “match” their etiological contribution
profile. This can, in practice, be achieved by
prior examination of (for example) key
biomarkers in the blood or expression of
g e n e s  i n  a  m i c r o a r r a y ;  a n d
extemporaneously preparing the mixture of
ingredients that “match” the profile.
However, it can be readily appreciated that
conventional therapy using single API’s
does not follow this paradigm. The
necessity of such “tailor made”
extemporaneous preparations using a
combination of excipients actually assumes
lesser significance because such a
combination of excipients meets the criteria
of promiscuity in targeting multiple
pharmacologic targets.
It should be readily apparent that; should such
a formulation of ostensibly “non active”
substances as outlined in this manuscript
demonstrate a significant improvement in
biomarkers in patients with type 2 diabetes in a
controlled clinical study; future formulations
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containing “active” pharmacological drugs that
are formulated with one or more of these
“bioactive excipients” must unequivocally
demonstrate that the clinical effect
demonstrated by the “active” is not dependent
on the inclusion of such “bioactive excipients”
in the formulation. For this purpose, the
placebo must contain the “bioactive
excipients”.
NOTE
The content of the manuscript is the subject of
Indian Patent Appl ica t ion number
66/MUM/2010 dated 1/7/2010 entitled “Anti-
Diabetic formulation” by the Author.
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